Literature review of the efficacy and safety of hyperthermic intraperitoneal perfusion chemotherapy after cytoreductive surgery in the treatment of pseudomyxoma peritonei.
- Author:
Ming-chen BA
1
;
Shu-zhong CUI
;
Fu-tian LUO
;
Wen-Wei OUYANG
;
Yun-Qiang TANG
;
Yin-Bing WU
;
Hong-Sheng TANG
Author Information
- Publication Type:Journal Article
- MeSH: Chemotherapy, Cancer, Regional Perfusion; methods; Humans; Peritoneal Neoplasms; drug therapy; surgery; Postoperative Care; Pseudomyxoma Peritonei; drug therapy; surgery; Treatment Outcome
- From: Chinese Journal of Gastrointestinal Surgery 2011;14(2):132-135
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluated the safety and efficacy of hyperthermic intraperitoneal perfusion chemotherapy(HIPC) in the prevention and treatment of pseudomyxoma peritonei (PMP) recurrence after cytoreductive surgery(CRS).
METHODSStudies published in English before 2010 on HIPC after CRS for PMP were searched in PubMed database. Each study was carefully evaluated based on pre-determined criteria. Study results were comprehensively displayed in a form. A descriptive systematic review was performed.
RESULTSA total of 11 studies were included. The median survival time of patients in these studies ranged from 25.6 months to 156 months. The ranges of 1-year, 2-year, 3-year, 5-year, and 10-year survival rates were 72%-100%, 55%-96%, 59%-96%, 52%-96%, and 55%-96%, respectively. The overall complication rate ranged from 2%-15%, and the total perioperative mortality were from 0 to 7%.
CONCLUSIONHIPC after CRS is effective and safe for patients with PMP.
